Add to Cart
Red blood cells contain hemoglobin, which enables them to carry oxygen from the lungs and transport it to all parts of the body. When the number of red blood cells drops, the blood cannot carry enough oxygen to deliver sufficient oxygen to the body's tissues, causing symptoms of anemia, which can make people feel tired and weak.
There are several types of anemia, each with its cause, which may be a temporary symptom or a long-term problem, ranging in severity from mild to severe, with signs and symptoms varying depending on the cause. At first, the anemia may be so mild that it is not easily detectable, but as it worsens, so do the symptoms. And Anemia is the most common hematologic disorder in general practice.
Sotatercept (also known as ACE-011) is a glycosylated dimeric fusion protein consisting of the extracellular structural domain of the human type IIA activator receptor (ActRIIA) and the fragment crystallizable (Fc) domain of human IgG1. Protein-based drug candidates act as ligand traps that bind competitively to activin A and other members of the transforming growth factor β superfamily, thereby blocking signaling through ActRIIA.
In animal models, the use of sotatercept increased hemoglobin (Hb) and hematocrit levels, and these findings have stimulated the interest of researchers in sotatercept as a potential treatment for patients with anemia and other disorders characterized by ineffective erythropoiesis. Creative BioMart offers this recombinant fusion protein (sotatercept) to researchers in the fields of anemia, leukemia, solid tumors, and multiple myeloma.
In practice, sotatercept can act as a ligand trap to inhibit the negative regulator of late erythropoiesis in the transforming growth factor β superfamily and correct ineffective erythropoiesis. Moreover, the therapeutic effects of sotatercept have now been reported in a variety of anemia types.
- Chemotherapy-induced anemia (CIA), including metastatic breast cancer or advanced metastatic solid tumors
- Beta(β)-thalassemia in adults
- Anemia in patients with low-risk myelodysplastic syndromes
- Myelofibrosis anemia
- Myelodysplastic syndromes (MDS)
- Chronic myelomonocytic leukemia (CMML)
Not only has sotatercept demonstrated safety and tolerability in supportive therapies for anemia, leukemia, solid tumors, and multiple myeloma, but also in trials for patients with pulmonary arterial hypertension (PAH), sotatercept is considered a potential pillar therapy for patients with PAH and has shown great potential for clinical use.
As experts in recombinant therapeutic proteins, it is Creative BioMart's responsibility to continue to provide researchers with high-quality therapeutic proteins, which of course include sotatercept, a recombinant fusion protein with great clinical potential. If you need to purchase the product or have questions about the product we provide, you can contact our staff by submitting information online or sending an email, and we will contact you as soon as we receive your information to provide you with the most appropriate solution.